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resulting in cost-effectiveness different to that of younger cohorts that receive the 
complete intervention: multi-cohort models can include both these “complete” and 
“partial” cohorts. Some multi-cohort models described as population models impose 
ﬁ nite time horizons at which the intervention is assumed to cease, although health 
effects are typically assessed until death. ANALYSIS: If cost-effectiveness differs 
between partial and complete cohorts, then the overall cost-effectiveness estimate from 
a multi-cohort model will depend on the relative numbers of partial and complete 
cohorts. The total number of complete cohorts depends on how long the intervention 
is used, which is uncertain. Therefore, the overall estimate may depend, in part, on 
the number of future cohorts assumed. The appropriateness of time horizons depends 
on whether a cross-sectional or a longitudinal cohort approach is used. Assuming an 
intervention ceases at a time horizon is unrepresentative of actual implementation and 
may result in biased cost-effectiveness estimates for curtailed cohorts. CONCLUSION: 
Multi-cohort modeling is advocated as being more representative of actual implemen-
tation. However, a single cost-effectiveness estimate for multiple cohorts necessarily 
implies an aggregation of estimates. Such aggregation leaves estimates sensitive to 
assumptions of the number of cohorts included, can hide useful information, and lead 
to nonoptimal policy choices. We suggest cost-effectiveness estimates for the complete 
and incomplete cohorts should not be aggregated, but reported separately. Implemen-
tation time horizons should not be used in longitudinal cohort-based modeling in 
cost-effectiveness analysis.
BI3
COMMON AND AVOIDABLE ERRORS IN ECONOMIC MODELING: A 
REVIEW OF THE FREQUENCY AND IMPACT OF MODELING MISTAKES
Taylor M, Kenworthy J, Lewis L
York Health Economics Consortium, York, North Yorkshire, UK
BACKGROUND: Cost-effectiveness models are often used to predict the costs and 
health outcomes that are likely to be associated with various different interventions. 
Models are a useful tool for representing the detailed and complex “real world” in a 
more simple and understandable structure. While models do not claim to necessarily 
create an exact replica of the real world, they can be useful in demonstrating the 
relationships and interactions between various different factors. However, developers 
of models often consciously, and unconsciously, make assumptions that are avoidable 
and may bias the results of a model. METHODS: A review was undertaken on a 
random selection of published models in different disease areas to aim to identify the 
frequency of typical “errors” in economic models. In addition, a simple model was 
developed and used to explore the relative impact of different types of errors in models. 
Each type of error was examined for its likely impact on the model’s overall ﬁ ndings 
and conclusions. This helped to gain a greater understanding of both the frequency 
of different errors and their magnitude of effect. RESULTS: Mistakes are commonly 
observed in economic models. These were often due to limitations in scope of the 
model, but all were found to be avoidable given unlimited time and data availability. 
As well as identifying “major” errors in models, the review also identiﬁ ed many 
common errors, such as excluding “half cycle correction,” that often have very little 
impact on a model’s results, relative to other common errors. CONCLUSIONS: While 
many errors in economic models are frequent, many errors often go unnoticed and 
have signiﬁ cant impact upon a model’s results. This analysis has highlighted the rela-
tive importance of each type of error and has provided suggestions as to how these 
might be avoided.
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OBJECTIVES: Discrepancies in diagnosis, treatment, or prognosis may emerge among 
physicians. a known decision-making bias is the tendency to shift personal opinion 
either toward or away from a previous opinion. We sought to evaluate such biases in 
the context of second-opinion medical consultations. METHODS: We distributed a 
survey questionnaire to a nationwide sample of orthopedic surgeons and neurologists. 
The questionnaires presented eight scenarios, each with conventional treatment 
options with no clear-cut preference. In four scenarios, the physicians were told that 
a previous opinion had already been given by another physician, or that a second 
opinion will be given, and the other four scenarios were used as controls. The physi-
cians’ responses were coded according to the level of intervention (conservative to 
interventional). RESULTS: 172 orthopedic surgeons and 160 neurologists ﬁ lled out 
the questionnaires, which represent about 50% of these specialties in Israel. In the 
orthopedic questionnaire, when a ﬁ rst opinion had already been given, there was a 
shift toward a more interventionist treatment (P < 0.05). This was especially prominent 
when the ﬁ rst opinion was known to the second physician. When the patient intended 
to seek a second opinion, there was a shift toward a more conservative treatment. No 
such effect was found among neurologists. CONCLUSIONS: Physicians’ judgment 
may be affected by another physician’s opinion (compared to their choices without a 
ﬁ rst opinion). This bias mainly tends toward a more interventionist treatment. Due 
to the immense impact of any decision on patient health and resource use, further 
research should address such biases and develop tools to address them. 
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OBJECTIVES: Regulators and payers view randomized controlled trials (RCT) as the 
gold standard for establishing the beneﬁ t/risk of new drugs. However, they are increas-
ingly interested in real-world data (RWD) due to their external validity. This survey 
explored stakeholders’ perceptions and emerging trends in the area of RWD. 
METHODS: We identiﬁ ed relevant literature since 2006 via Google Scholar and 
manual search, and reviewed it based on several topics: types of RWD, pros and cons 
of different approaches, and impact of new statistical techniques and technology on 
availability and quality of RWD. We then conducted 45–60 min in-depth, semistruc-
tured discussions with 17 experts from Academia, HTA bodies, health insurance, 
research organizations, and pharmaceutical industry—from the UK, France, Germany, 
the The Netherlands, and the United States. Their views about value and future direc-
tions of RWD approaches were elicited. RESULTS: Experts unanimously thought that 
RCTs would remain a mandatory approach for the foreseeable future due to the limi-
tations of RWD, mainly potential for confounding. New study designs (e.g., random-
ized database studies) and statistical techniques (e.g., high-dimensional propensity 
scoring) remove confounding only partially and need to gain credibility. There was a 
strong view that, while registries have been the reference source of observational data, 
there is an opportunity for (claims) database and electronic medical records to form 
an efﬁ cient platform for automatic, real-time analysis of naturalistic data. Despite a 
few good examples, it will, however, require time to resolve technical difﬁ culty of 
linking databases and, crucially, the challenges of data ownership and privacy issues. 
Several experts predict the short-term rise of at-home monitors, “smart pills,” and 
“smart phones” that automatically feed into databases, and the increased use of data 
from Google Health and Microsoft HealthVault. CONCLUSIONS: RWD may eventu-
ally become the new gold standard in drug development, but this will occur only 
through incremental progress.
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OBJECTIVES: Prices of recently launched targeted therapies are relatively high and 
patient access differs between European countries. Advanced renal cell cancer (aRCC) 
is a rare malignancy with poor prognosis for which four such drugs are available: 
sunitinib, sorafenib, bevacizumab, and temsirolimus. We investigated relations 
between funding decisions of national health authorities and patient access to these 
treatments. METHODS: We reviewed Web sites of health authorities in France, 
Germany, Italy, and UK. Data on drug utilization from June 2006 to July 2009 were 
extracted from the Synovate Oncology Monitor, an ongoing prescription database 
based on doctors’ diaries. Total sample size varied between countries, from 7766 to 
9463 patients within the year ending 2009 Q2. RESULTS: Sunitinib was granted 
restricted recommendation by NICE (UK) in March 2009, but other treatments were 
not assessed during study period. All drugs were ﬁ nanced through payment-for-per-
formance schemes (P4PS) with a registry in Italy. In France, bevacizumab and temsi-
rolimus were reimbursed on top of DRGs and in Germany only bevacizumab. 
Sunitinib was the ﬁ rst line treatment in 62%, 50%, 47%, and 31% of drug-treated 
patients in France 2006Q3–2009Q2), Germany, Italy, and UK, respectively, followed 
by temsirolimus in France and Germany but sorafenib in Italy. Sorafenib was the most 
widely used second line treatment in Germany and Italy. In France, temsirolimus was 
used off-label in ﬁ rst line and bevacizumab before funding decision in aRCC was 
granted. In UK, many patients remained untreated. CONCLUSIONS: Funding on top 
of DRGs in France contributed to early uptake and off-label usage. P4PS were associ-
ated with enhanced drug uptake in Italy. In UK, the lack of assessment by NICE 
prevented patient access, which raises concern about the current ﬁ nancing system. The 
large differences in patient access to recently approved cancer treatments raise the 
issue of equity and health outcomes associated with innovative drugs.
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OBJECTIVES: Payer expectations for reimbursement from novel drugs are constantly 
increasing. Understanding these is crucial during evidence generation. Expectations in 
terms of clinical outcomes vary across EU countries. This study compared payer 
awareness and expectations in two disease areas with contrasting prevalence and 
subsequent impact on health-care budgets, and thus their impact on reimbursement. 
METHODS: The study was conducted in EU5 markets. Opinions of 36 stakeholders 
were collected via telephone interviews. Value drivers for new drugs were tested 
including unmet need, clinical data—safety and efﬁ cacy, cost-effectiveness, budget 
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impact, price, price against comparator, and innovation. The results in the two disease 
areas were separately analyzed and then compared with each other qualitatively on 
the basis depth of the responses. RESULTS: Awareness about the evidence expecta-
tions were seen to vary substantially between the disease areas. Payers were seen to 
be far more conscious in the high-burden disease area. Of the 12 stakeholders inter-
viewed for the high-burden disease area (cardiovascular disease used as an example), 
all of them could provide an in-depth understanding of the value drivers for a new 
drug. On the other hand, of the stakeholders interviewed from a low-burden disease 
area within urology, a very small part of the sample (n = 2) was able to provide details 
about necessary expectations for the indication. CONCLUSIONS: The variation in 
awareness among payers in disease areas tends to affect the clinical outcomes that are 
presented by the drug manufacturer for a novel drug for the indication. The low 
awareness regarding evidence expectations in disease areas with low budgetary impact 
may lead to lower quality of evidence being accepted for reimbursement. This needs 
to be further investigated. 
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OBJECTIVES: The number of economic-evaluations (EE) increases but their role in 
decision-making remains unclear. Our literature review of the use of EE in decision-
making at macro-level aimed to analyze the methods presented in the articles and to 
investigate differences within and between countries regarding the use of EE, its facili-
tators and barriers. METHODS: We searched major databases (PubMed, Web-of-
Science, Euronheed, EconLit) in seven languages, without time limit, using keywords 
related to economics, health care policy decision-making, and outcomes research. 
Abstracts were screened according to four criteria reﬂ ecting the objectives of our 
review. Selected articles were analyzed and compared using a checklist of items related 
to study context (period, location, domain . . .), methods (population, design . . .), 
and outcomes (use of EE, facilitators, barriers . . .). RESULTS: Twenty-nine articles 
were selected. Most reported single-country- (24), mainly developed-country-studies 
(20). Five multi-country-studies compared countries of Europe, the USA and Latin-
America. The studies’ population generally included public or private health authori-
ties and used questionnaires (10), interviews (6), focus-groups (1), observations (4) or 
a combination of interviews and other methods (8). The main facilitator to using EE 
in decision-making was governmental/institutional incentives (UK and Australia). 
Although the use of EE has increased since the late 1990s, barriers remain, without 
apparent variation, overtime and between countries. Most relate to the accessibility 
and acceptability of EE. CONCLUSIONS: Decision-makers are increasingly aware of 
the importance of using EE in their practice. Despite large differences in the level of 
EE use between countries, barriers are very similar. Studying these barriers could 
narrow gaps between researchers and decision-makers and encourage governmental 
incentives to using EE. Consequently, we decided to develop a methodology for assess-
ing the use of EE in radiotherapy decision-making, a domain where many EE have 
been undertaken, without actually investigating their use. This study will be conducted 
in France, and in European or developing-countries.
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OBJECTIVES: In cost-utility analyses (CUA), utility values are rarely available for the 
entire patients sample and they are generally predicted using a “mapping” interpola-
tion from a functional status questionnaire, known for the entire sample. This 
mapping method is not accounted for in pharmaceutical industry and in literature 
studies, when building conﬁ dence regions around the utility and the incremental cost-
utility ratio, leading to a wrong conﬁ dence region and consequently, to a wrong 
decision-making. The purpose of this paper is to build a conﬁ dence interval (CI) 
around the mean utility, accounting for the uncertainty coming from the “mapping” 
interpolation. METHODS: Analytical and bootstrap methods are developed to handle 
the fact that values are interpolated. Linear, multilinear, and nonlinear mapping are 
considered. Monte Carlo experiments are carried out to compare the performance of 
these methods. These methodologies are applied on data issued from an observational 
study dealing with prostate cancer treatment. Utility is assessed with Standard Gamble 
method and some of these values are interpolated from the questionnaires: EORTC 
QLQC-30; IPSS and IIEF-5; SF-36 and Visual Analogic Scales. RESULTS: Monte 
Carlo experiments show that the analytic and bootstrap 95% CI display coverage 
between 94% and 96% for various sample sizes. If mapping is not accounted for 
(“naive method”), the coverage is between 20% and 40%. The cross validation shows 
similar results. From prostatectomy data, the utility is explained by SF-36, role func-
tioning, diarrhea, and age. For instance, mean utility equals 0.94. The analytic and 
bootstrap CIs equal [0.59, 1.51] and [0.51, 1.63] respectively. The naive interval 
equals [0.95, 1.15]. CONCLUSIONS: In CUA, decision-making based on utility 
values interpolated from mapping is not reliable: a naive interval would lead to a 
serious mistake. The uncertainty due to mapping has to be accounted for. Our analytic 
and bootstrap procedures, integrating the mapping, provide very accurate results.
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BACKGROUND: Two types of mapping exercises have been suggested to translate 
data from the short-form health instrument SF-12 into measurements for the EQ-5D 
instrument. One of the trends associates SF-12 data directly to the EQ-5D index, 
whereas a second approach suggests a response mapping method where SF-12 data 
have been mapped to the ﬁ ve domains of the EQ-5D questionnaire. OBJECTIVES: 
To improve the current response mapping approach and provide a comparison 
between the direct and the response mapping approaches to the EQ-5D. METHODS: 
Five multinomial logit regressions were implemented to estimate the association 
between SF-12 variables and each of the EQ-5D domains. Predicted EQ-5D responses 
were estimated using a Monte Carlo method. a parameter uncertainty approach was 
introduced to calculate conﬁ dence intervals for the predicted EQ-5D index. The direct 
mapping approach for the comparison was also conducted. Several large data sets 
were used for internal and external validation. Actual versus predicted EQ-5D index 
were compared using mean square error (MSE), mean absolute error (MAE), and 
conﬁ dence intervals. RESULTS: In the internal validation data set, both the response 
and direct mapping predicted a similar mean EQ-5D index, but the response mapping 
yielded a smaller MSE of 0.018 compared to 0.020 in the direct mapping, and a 
smaller MAE of 0.091 in the response mapping compared with 0.105 in the direct 
mapping method. Using the external validation data set, the MSE and MAE were one 
decimal point less in the response compared to the direct mapping. CONCLUSIONS: 
The revised response approach provided marginally better results than the direct 
mapping method. The response method can be implemented to country-speciﬁ c 
EQ-5D data with available value sets. To facilitate the implementation of the revised 
response mapping algorithm, a Stata command has been programmed.
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OBJECTIVES: Treatments of ocular hypertension (OHT) and glaucoma aim mainly 
at maintaining the patient’s visual function and related quality of life (QoL). However, 
it is not known to what extent the disease progression impacts the health-related QoL. 
Using recent publications, the objectives were to 1) derive a range of EQ-5D utility 
scores in OHT/glaucoma patients; (2) establish a direct, quantitative link between the 
mean defect in perimetry (MD) measured in decibels (db) and the utility loss; and (3) 
estimate the utility level of patients reaching a glaucoma stage. METHODS: The 
glaucoma stages were characterized using MD thresholds of 0 db (OHT), 0–6 db 
(early glaucoma), 6–12 db (moderate), 12–22 db (advanced), and >22 db (legal blind-
ness), as per the Hodapp classiﬁ cation. An algorithm allowing to derive EQ-5D utility 
scores from the eight mean subscale scores to the SF-36 (Ara and Brazier 2008) was 
applied to the range of SF-36 scores published in a systematic review of QoL in 
glaucoma (Mills 2009). Besides, the same algorithm was used to estimate the utility 
loss corresponding to a MD of 1 db, based on a regression model assessing the correla-
tion between visual function and QoL in glaucoma patients (Lin and Yang 2010). 
RESULTS: Over eight studies in OHT/glaucoma patients, utility scores ranged from 
0.65 to 0.89. Based on a signiﬁ cant regression coefﬁ cient for the SF-36 Role Physical 
subscale, a utility loss of 0.0295/db was calculated. Applying this utility loss/db to the 
predeﬁ ned thresholds, the ranges of unadjusted utility scores expected per glaucoma 
stage equal: 0.72–0.90 (early), 0.55–72 (moderate), 0.25–0.55 (advanced), and <0.25 
(blindness), assuming a baseline utility of 0.90 for OHT. CONCLUSIONS: These 
utility scores per disease stage are consistent with published direct measures of HUI3. 
The estimated utility loss per db is sizeable and could be implemented in cost-utility 
models where disease progression is tracked.
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OBJECTIVES: Anchor-based methods are frequently used for determining the 
minimal important difference (MID) of scales employed to measure patient-reported 
outcomes (PRO). The anchor may, e.g., consist of a global rating by the patient or 
the doctor or of a clinical measure closely related to the issue to be measured. The 
role of the psychometrical properties of the anchor has been rarely studied in this 
context. Aim of this contribution is to shed more light on the relationship between 
